Gene Therapy Reimbursement: Is Blindness A Bad First Test?
Executive Summary
The first gene therapy approval could be coming soon – followed shortly by the first ever gene therapy coverage decision. An Express Scripts executive argues that the tone may be affected by the initial indication.
You may also be interested in...
Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting
Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.
Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review
Voretigene neparvovec moves closer to being the first to market a gene therapy in the US with FDA advisory committee review on Oct. 12.
Spark Sets Sights On Bringing First Gene Therapy To Market In 2018
A BLA for a potential gene therapy to correct vision loss due to certain inherited retinal disease has been accepted by FDA with a Jan. 12 PDUFA date. The proposed trade name is Luxturna.